A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Titre officiel

A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers

Sommaire:

This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

Description de l'essai

Primary Outcome:

  • Percentage of Participants with Adverse Events
Secondary Outcome:
  • Serum Concentration of Runimotamab
  • Area Under the Serum Concentration vs. Time Curve (AUC) of Runimotamab
  • Maximum Observed Serum Concentration (Cmax) of Runimotamab
  • Minimum Observed Serum Concentration (Cmin) of Runimotamab
  • Clearance (CL) of Runimotamab
  • Volume of Distribution at Steady State (Vss) of Runimotamab
  • Objective Response (OR) as Determined by the Investigator According to Response Evaluation Criteria In Solid Tumours v1.1 (RECIST v1.1)
  • Duration of Response (DOR)
  • Anti-Drug Antibody (ADA) Levels of Runimotamab

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer